Brii Biosciences Limited · HKEX:2137

Brii Biosciences — H.C. Wainwright 1st Annual Mental Health Conference (June 2022)

14 slides from Brii Biosciences's conference presentation, Jun 27, 2022

  1. Slide 1: Corporate Presentation at H.C. Wainwright 1st Annual Mental Health Conference

    JUNE 27, 2022 Corporate Presentation at H.C. Wainwright 1st Annual Mental Health Conference - Zhi HONG PhD, Chairman & CEO

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been delivered for information purposes only and upon the express understanding that recipients of this presentation will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase sec

  3. Slide 3: Brii Bio Vision & Mission

    Brii Bio Vision & Mission Our vision is to Our mission is to Be the leading public health-inspired and infectious Tackle world’s biggest public health challenges with disease / CNS disease-focused biotech Breakthrough innovation & insight Continue to focus on Prioritize the access to Leverage patien

  4. Slide 4: Brii Bio's pipeline investment is aligned with China vs. Global market potential

    Brii Bio’s pipeline investment is aligned with China vs. Global market potential Without effective cure, many diseases’ prevalence and burden are increasing China is a major market for HBV US and EU are the major markets for HIV Cure and MDR/XDR hospital infection and CNS diseases infections Brii Ri

  5. Slide 5: Broad pipeline addressing large disease burdens & social stigmas

    Broad pipeline addressing large disease burdens & social stigmas Regulatory Indication Program Preclinical IND Phase 1 Phase 2 Phase 3 NDA/BLA Brii Rights Partners Authority Infectious Disease Programs BRII-179/BRII-835 (VIR-2218) NMPA Greater China Combination Hepatitis B BRII-179 (VBI-2601)/PEG-IF

  6. Slide 6: World-class leadership team with a proven track record of success

    World-class leadership team with a proven track record of success Leadership team Lianhong XU Qing ZHU Coy STOUT David MARGOLIS Karen NEUENDORFF SVP SVP SVP, U.S. Market Access VP, Infectious Chief People Officer Medicinal Chemistry Biopharma and Patient Advocacy Diseases Therapy Area Former VP of M

  7. Slide 7: Depression is associated with many CNS and other chronic diseases

    Depression is associated with many CNS and other chronic diseases The burden of depression is on the rise globally Postpartum depression affects both woman health and neonate development Up to one-third of individuals Large and growing PPD patient base for with a serious medical both treatment and p

  8. Slide 8: A silent and parallel pandemic of mental illnesses

    A silent and parallel pandemic of mental illnesses On March 2, 2022, WHO reported a massive increase of 25% in the prevalence of anxiety & depression dis- orders worldwide compared to pre-pandemic period On March 14, 2022, U.S. Senator Tammy Baldwin and colleagues introduced the bipartisan, Into the

  9. Slide 9: Brii Bio's insight for breakthrough innovation in CNS diseases areas

    Brii Bio’s insight for breakthrough innovation in CNS diseases areas Simple, rapid, sustained and adherence-assured treatment options Reliable mechanism of action – GABAA PAM Directly observed therapy: assured adherence • GABAA receptor is a known target with multiple classes of anti-depressants • S

  10. Slide 10: Zulresso is the only approved therapeutic for PPD, but it is complicated

    Zulresso is the only approved therapeutic for PPD …but it is a very complicated treatment option Mechanism of action of Allopregnanolone in PPD • Allopregnanolone (also known as brexanolone) is a naturally occurring neuroactive steroid that acts as a positive allosteric modulator (PAM) of GABA's act

  11. Slide 11: BRII-296 and BRII-297 A new treatment paradigm & differentiated value proposition

    BRII-296 and BRII-297 A new treatment paradigm & differentiated value proposition Program Modality MOA Pre-clinical Ph 1 Ph 2/3 Asset Rights Next Milestones BRII-296 GABAA receptor Wholly owned Ph2/3 dose selection PPD Treatment PAM Novel long-acting BRII-296 GABAA receptor parenteral formulation Wh

  12. Slide 12: Brii Bio is aiming to build a broad pipeline with BRII-296/BRII-297

    Brii Bio is aiming to build a broad pipeline with BRII-296/BRII-297 PPD PPD Treatment & Prevention PMDD MDD • BRII-296 uniquely differentiated single treatment paradigm PTSD BPD Other Depressive Disorders • Broader and more precise TPPs BRII-296/297 • Synergy between BRII-296 & BRII-297 CDKL5 CDD GA

  13. Slide 13: Brii Bio's ESG highlights

    Brii Bio’s ESG highlights Society recognitions and awards Public Health Contributions Commitment to Public Private Partnership • Brii supported and collaborated with public health stakeholders in • Best-in-Class Public/Private Partnerships: Brii worked closely with both US and China, achieved the fi

  14. Slide 14: Closing. Q&A and Final Remarks

    Closing. Q&A and Final Remarks Contact: [email protected]

Brii Biosciences — H.C. Wainwright 1st Annual Mental Health Conference (June 2022) on 6ix